Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study)

Michele Cortellaro, E. Cofrancesco, C. Boschetti, F. Cortellaro, M. Mancini, M. Mariani, R. Paoletti

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Aim of the study. We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. Design. In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. Results. Plasma fibrinogen significantly decreased after treatment with the combinations' fluvastatin + bezafibrate (-14 and -16%) and with bezafibrate monotherapy (-9%). No significant reduction was observed after fluvastatin monotherapy (-4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. Conclusions. The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.

Original languageEnglish
Pages (from-to)549-553
Number of pages5
JournalThrombosis and Haemostasis
Volume83
Issue number4
Publication statusPublished - 2000

Fingerprint

fluvastatin
Bezafibrate
Plasminogen Inactivators
Hyperlipidemias
C-Reactive Protein
Fibrinogen
Coronary Artery Disease
Plasminogen Activator Inhibitor 1
Stable Angina
Therapeutics
LDL Cholesterol
Multicenter Studies
Triglycerides

Keywords

  • Coronary artery disease
  • Fibrate
  • Fibrinogen
  • Statin

ASJC Scopus subject areas

  • Hematology

Cite this

Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). / Cortellaro, Michele; Cofrancesco, E.; Boschetti, C.; Cortellaro, F.; Mancini, M.; Mariani, M.; Paoletti, R.

In: Thrombosis and Haemostasis, Vol. 83, No. 4, 2000, p. 549-553.

Research output: Contribution to journalArticle

@article{7c016c4ace9a4dc29d7858035c943f76,
title = "Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study)",
abstract = "Aim of the study. We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. Design. In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. Results. Plasma fibrinogen significantly decreased after treatment with the combinations' fluvastatin + bezafibrate (-14 and -16{\%}) and with bezafibrate monotherapy (-9{\%}). No significant reduction was observed after fluvastatin monotherapy (-4{\%}). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. Conclusions. The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.",
keywords = "Coronary artery disease, Fibrate, Fibrinogen, Statin",
author = "Michele Cortellaro and E. Cofrancesco and C. Boschetti and F. Cortellaro and M. Mancini and M. Mariani and R. Paoletti",
year = "2000",
language = "English",
volume = "83",
pages = "549--553",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "4",

}

TY - JOUR

T1 - Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study)

AU - Cortellaro, Michele

AU - Cofrancesco, E.

AU - Boschetti, C.

AU - Cortellaro, F.

AU - Mancini, M.

AU - Mariani, M.

AU - Paoletti, R.

PY - 2000

Y1 - 2000

N2 - Aim of the study. We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. Design. In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. Results. Plasma fibrinogen significantly decreased after treatment with the combinations' fluvastatin + bezafibrate (-14 and -16%) and with bezafibrate monotherapy (-9%). No significant reduction was observed after fluvastatin monotherapy (-4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. Conclusions. The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.

AB - Aim of the study. We studied the effects of fluvastatin and bezafibrate in monotherapy and in combination on plasma fibrinogen, t-plasminogen activator inhibitor (PAI-1) and C reactive protein (CRP) in patients with coronary artery disease (CAD) and mixed hyperlipidaemia. Design. In this randomised, double blind, multicentre trial 333 patients with stable angina pectoris or previous myocardial infarction or coronary revascularisation and mixed hyperlipidaemia (LDL-cholesterol 135-250 mg/dl and triglycerides (TG) 180-400 mg/dl) were randomised to fluvastatin 40 mg, bezafibrate 400 mg, fluvastatin 20 mg + bezafibrate 400 mg or fluvastatin 40 mg + bezafibrate 400 mg treatments for 24 weeks. Results. Plasma fibrinogen significantly decreased after treatment with the combinations' fluvastatin + bezafibrate (-14 and -16%) and with bezafibrate monotherapy (-9%). No significant reduction was observed after fluvastatin monotherapy (-4%). No significant changes were observed in PAI-1 and CRP plasma levels. Combination therapy significantly decreased both LDL-C and TG, and significantly increased HDL-C. Conclusions. The combined effects on fibrinogen and plasma lipids achieved by fluvastatin and bezafibrate combination treatment might be more useful than the simple reduction of cholesterol in preventing ischaemic cardiovascular disease.

KW - Coronary artery disease

KW - Fibrate

KW - Fibrinogen

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=0034035848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034035848&partnerID=8YFLogxK

M3 - Article

C2 - 10780315

AN - SCOPUS:0034035848

VL - 83

SP - 549

EP - 553

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 4

ER -